Nicholas J. Sarlis Net Worth

What's Nicholas Sarlis's mailing address?

Nicholas's mailing address filed with the SEC is C/O SELLAS LIFE SCIENCES GROUP, INC., 15 WEST 38TH STREET, 10TH FLOOR, NEW YORK, NY, 10018.

Insiders trading at SELLAS Life Sciences Inc

Over the last 7 years, insiders at SELLAS Life Sciences Inc have traded over 74,616$ worth of SELLAS Life Sciences Inc stock. The most active insiders traders include John Varian、Jane Wasman、David A Scheinberg. On average, SELLAS Life Sciences Inc executives and independent directors trade stock every 205 days with the average trade being worth of 6,842$. The most recent stock trade was executed by Angelos M. Stergiou on 5 December 2022, trading 6,494 units of SLS stock currently worth 16,949$.

What does SELLAS Life Sciences Inc do?

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.

SELLAS Life Sciences Inc executives and stock owners

SELLAS Life Sciences Inc executives and other stock owners filed with the SEC include:

• Angelos Stergiou,
  President, Chief Executive Officer, Director
• Dr. Angelos M. Stergiou M.D., ScD h.c.,
  Founder, Pres, CEO & Director
• Barbara Wood,
  Executive Vice President, General Counsel, Corporate Secretary
• Barbara A. Wood,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Dragan Cicic M.D., MBA,
  Sr. VP of Clinical Devel.
• John Burns,
  Interim Principal Accounting Officer, Vice President - Finance, Corporate Controller
• Dr. Dragan Cicic,
  Sr. VP of Clinical Devel.
• Jane Wasman,
  Independent Chairman of the Board
• John Varian,
  Independent Director
• Robert Van Nostrand,
  Independent Director
• David Scheinberg,
  Director
• Dragan Cicic,
  Senior Vice President - Clinical Development
• Jörg W. Breitkopf,
  Head of Clinical Operations
• Robert M. Francomano,
  Sr. VP & Chief Commercial Officer
• John Thomas Burns CPA,
  Sr. VP of Fin. & Chief Accounting Officer
• David D. Moser,
  VP of Legal Affairs
• Jörg W. Breitkopf,
  Head of Clinical Operations
• Dr. Christopher R. Shackleton,
  Director of Clinical and Bus. Operations
• Martin G. Baum,
  Chief Operating Officer
• John Thomas Burns CPA, CPA,
  VP of Fin., Corp. Controller & Chief Accounting Officer
• Fabio Lopez,
  Director
• Nicholas J. Sarlis,
  Chief Medical Officer and SVP
• Robert Francomano,
  Chief Commercial Officer
• Fabio Eqc Private Markets S...,
  
• Stephen F Ghiglieri,
  Director
• Gregory M Torre,
  CRO and SVP
• Fabio Eqc Private Markets S...,
  
• Gene Mack,
  CFO and Treasurer
• Katherine Bach Kalin,
  Director